Related Experiment Video
Updated: May 14, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Intraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia
N H Andrew1, D Kearney, D Selva
1South Australian Institute of Ophthalmology and the Department of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, South Australia. nick.h.andrew@gmail.com
Eye (London, England)
|January 26, 2013
Summary
Intraorbital triamcinolone acetonide injections effectively treated orbital reactive lymphoid hyperplasia (RLH) in 80% of patients. Repeat injections may be necessary for complete symptom resolution in some cases.
Area of Science:
- Ophthalmology
- Endocrinology
Background:
- Orbital reactive lymphoid hyperplasia (RLH) is a benign lymphoid proliferation.
- Treatment options for orbital RLH can be limited, necessitating exploration of novel therapeutic approaches.
Observation:
- This study evaluated intraorbital triamcinolone acetonide injections as a primary treatment for orbital RLH.
- A retrospective, single-centre, interventional case series design was employed.
Findings:
- Complete resolution of symptoms and signs was observed in 80% of patients following intraorbital triamcinolone acetonide injections.
- Resolution was achieved with one or two injections in most cases, though one patient developed new lesions after treatment.
- Radiological resolution was confirmed in one case.
Implications:
- Intraorbital corticosteroid injection presents a potentially effective first-line therapy for anterior orbital RLH.
- Further investigation in larger, prospective studies is warranted to confirm these findings and optimize treatment protocols.
